Unlocking the secrets of HIV's persistence

May 22, 2018, Brigham and Women's Hospital
HIV (yellow) infecting a human immune cell. Credit: Seth Pincus, Elizabeth Fischer and Austin Athman, National Institute of Allergy and Infectious Diseases, National Institutes of Health

Thanks to advances in the development of anti-retroviral therapy (ART), patients with HIV are living longer than ever before. And yet, even in patients on very effective, long-term ART, HIV persists, requiring patients to take antiviral medication life-long. It's thought that the virus establishes a "persistent reservoir" of infected cells that can survive almost indefinitely. A new study by investigators at Brigham and Women's Hospital explores how the virus gets this foothold, identifying cellular survival programs that become activated in infected cells, and providing a potential target for future therapy. Their results are published this week in Immunity.

"Our work shows that these HIV reservoir upregulate anti-apoptosis molecules (molecules that are otherwise expressed in cancer) that maintain their long-term survival," said Mathias Lichterfeld, MD, Ph.D., of BWH's Division for Infectious Diseases. "These findings point to clinical strategies that may reduce persisting viral reservoirs."

In collaboration with a group led by Steve Carr, Ph.D., from the Broad Institute of MIT and Harvard, Lichterfeld and colleagues used quantitative liquid chromatography-tandem mass spectrometry (LC-MS/MS)-based proteomics to take a detailed look at the proteins that were increased in cells infected with HIV. They found that BIRC5 and its partner OX40 were both involved in these cells' long-term survival.

BIRC5, also known as "survivin" is part of a family of molecules involved in cell death. It is naturally expressed in during embryonic development but generally turned off in . One exception to this generality is cancer: frequently turn BIRC5 back on and its presence is associated with resistance to chemotherapy. The new study shows BIRC5 may also help HIV-1- to escape cell death, and contribute to the ability of viral reservoir cells to persist for decades despite effective antiretroviral therapy.

In recent years, clinicians have reported cases of patients with HIV who have had aggressive chemotherapy that has temporarily reduced viral levels to undetectable levels, but HIV has rebounded in these patients. The current study points to a new approach: inhibition of the BIRC5-OX40 pathway may help reduce reservoirs of infected cells, and potentially offer a path forward to eliminating these persisting cells.

Explore further: Understanding HIV's persistence

More information: Hsiao-Hsuan Kuo et al, Anti-apoptotic Protein BIRC5 Maintains Survival of HIV-1-Infected CD4 + T Cells, Immunity (2018). DOI: 10.1016/j.immuni.2018.04.004

Related Stories

Understanding HIV's persistence

June 19, 2017
Most cells in the human body have a limited lifespan, typically dying after several days or weeks. And yet, HIV-1 infected cells manage to persist in the body for decades. Current treatment for HIV is very effective at suppressing ...

Study identifies population of stem-like cells where HIV persists in spite of treatment

January 12, 2014
Although antiviral therapy against HIV suppresses viral replication and allows infected individuals to live relatively healthy lives for many years, the virus persists in the body, and replication resumes if treatment is ...

Gene therapy using CAR T-cells could provide long-term protection against HIV

December 28, 2017
Through gene therapy, researchers engineered blood-forming stem cells (hematopoietic stem/progenitor cells, or HSPCs) to carry chimeric antigen receptor (CAR) genes to make cells that can detect and destroy HIV-infected cells. ...

Gene-edited stem cells show promise against HIV in non-human primates

April 19, 2018
Gene editing of bone marrow stem cells in pigtail macaques infected with simian/human immunodeficiency virus (SHIV) significantly reduces the size of dormant "viral reservoirs" that pose a risk of reactivation. Christopher ...

Top HIV cure research team refutes major recent results on how to identify HIV persistence

April 18, 2018
An international team focused on HIV cure research spearheaded by The Wistar Institute in collaboration with the University of Pennsylvania and Vall d'Hebron Research Institute (VHIR) in Barcelona, Spain, established that ...

Leukemia-causing retrovirus HTLV-1 vaccine a future possibility

April 13, 2018
A study appearing in the in Proceedings of the National Academy of Sciences gives new clues into how cancers like leukemia form from the retrovirus HTLV-1, as well as insights into the possible creation of a vaccine.

Recommended for you

New simulation tool predicts how well HIV-prophylaxis will work

June 14, 2018
A new mathematical simulation approach predicts the efficacy of pre- and post-exposure prophylaxis (PrEP) medications, which help prevent HIV infection. The framework, presented in PLOS Computational Biology by Sulav Duwal ...

Many at risk for HIV despite lifesaving pill

June 11, 2018
Multiple barriers may stop high-risk individuals from accessing an HIV drug that can reduce the subsequent risk of infection, according to a new University of Michigan study.

Active HIV in large white blood cells may drive cognitive impairment in infected mice

June 7, 2018
Macrophages, large white blood cells that engulf and destroy potential pathogens, harbor active viral reserves that appear to play a key role in impaired learning and memory in mice infected with a rodent version of HIV. ...

HIV vaccine elicits antibodies in animals that neutralize dozens of HIV strains

June 4, 2018
An experimental vaccine regimen based on the structure of a vulnerable site on HIV elicited antibodies in mice, guinea pigs and monkeys that neutralize dozens of HIV strains from around the world. The findings were reported ...

HIV study reveals new group of men at risk of infection

June 4, 2018
A group of men who may be underestimating their HIV risk has been identified in a new study.

Discovery reveals how cells try to control levels of key HIV protein

May 31, 2018
One of the many challenges in treating HIV is that the virus can lie dormant in cells, quietly evading immune detection until it suddenly roars to life without warning and begins replicating furiously. Salk Institute researchers ...

2 comments

Adjust slider to filter visible comments by rank

Display comments: newest first

Anonym330907
not rated yet Jun 05, 2018

I started using multiple sclerosis (MS) herbal remedy i purchased from Best Health Herbal Centre January this year. I only used it for a month and two weeks, my condition changed automatically, all my symptoms are gone. Remaining positive have helped me during this treatment. Now am living MS FREE.
Hope this will help somebody, remember, do your own research and make your own decisions based on information you have received and digested. Thanks to Best Health Herbal Centre for their amazing work. Forever Grateful!
Contact them via w ww .besthealthherbalcentre. com
sayemahmooda_gma
not rated yet Jun 05, 2018
My name is Mahmooda Sayed, I am from Texas,USA. I am sure this information will be useful to the general public on how my sister was cured from Genetic Herpes with the same herbal practitioner who also got me cured from HIV/AIDS,The medication was administered by Dr Zulu. He cures other diseases too. For further information visit Drmohamendherbalremedy@gmail.com, For those of us that would come back appreciating me or might need further information, the above name is my Facebook name or you can also write me mails at sayemahmooda@gmail.com

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.